Edwards suffers setback at EPO in heart-valve dispute with Meril
Edwards Lifesciences has suffered a significant setback in its ongoing heart-valve dispute with Indian competitor Meril Life Sciences after the EPO's Board of Appeal revoked one of Edwards' key patents in full. This decision overturns a previous ruling by the Opposition Division and has direct consequences for parallel UPC proceedings, which are currently under appeal. The revocation of EP 4 151 181 removes the basis for an injunction previously granted against Meril at the UPC.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.